Drugs for Appendiceal Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 66)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 1, Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
|
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
| 2 |
|
Durvalumab |
Approved, Investigational |
Phase 1, Phase 2 |
|
1428935-60-7 |
|
|
Synonyms:
|
| 3 |
|
Thalidomide |
Approved, Investigational, Withdrawn |
Phase 2 |
|
50-35-1 |
5426 |
|
Synonyms:
(+-)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(+-)-THALIDOMIDE
(±)-N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
(±)-THALIDOMIDE
1,3-DIOXO-2-(2,6-DIOXOPIPERIDIN-3-YL)ISOINDOLINE
2,6-DIOXO-3-PHTHALIMIDOPIPERIDINE
3-PHTHALIMIDOGLUTARIMIDE
Algosediv
ALPHA-(N-PHTHALIMIDO)GLUTARIMIDE
ALPHA-N-PHTHALYLGLUTARAMIDE
alpha-Phthalimidoglutarimide
Asidon 3
Asmadion
Asmaval
Bonbrain
Bonbrrin
Calmore
Calmorex
Celgene brand OF thalidomide
Contergan
Corronarobetin
Distaval
Distaxal
Distoval
Ectiluran
Enterosediv
Gastrinide
Glupan
Glutanon
Grippex
Hippuzon
Imida-Lab
Imidan
Imidene
Isomin
K-17
Kedavon
Kevadon
Lulamin
N-(2,6-DIOXO-3-PIPERIDYL)PHTHALIMIDE
Neaufatin
Neo
Neosedyn
Neosydyn
Nerosedyn
Neufatin
Neurodyn
Neurosedin
Neurosedym
Neurosedyn
Nevrodyn
Nibrol
Noctosediv
Noxodyn
|
N-Phthalimidoglutamic acid imide
N-Phthaloylglutamimide
N-Phthalylglutamic acid imide
N-PHTHALYL-GLUTAMINSAEURE-IMID
NSC-527179
NSC-66847
Pangul
Pantosediv
Poly-Giron
Polygripan
Predni-Sediv
Pro-ban M
Profarmil
Psycholiquid
Psychotablets
Quetimid
Quietoplex
Sandormin
Sedalis
Sedalis sedi-lab
Sedimide
Sedin
Sedisperil
Sedoval
Shin-naito S
Shinnibrol
Sleepan
Slipro
Softenil
Softenon
Talargan
TALIDEX
TALIDOMIDA
Talimol
Talismol
Telagan
Telargan
Telargean
Tensival
Thaled
Thalidomide
THALIDOMIDUM
Thalidomine usp26
Thalin
Thalinette
Thalomid
Theophilcholine
Valgis
Valgraine
Yodomin
Α-(N-PHTHALIMIDO)GLUTARIMIDE
Α-N-PHTHALYLGLUTARAMIDE
Α-PHTHALIMIDOGLUTARIMIDE
|
|
| 4 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2 |
|
33069-62-4 |
36314 |
|
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
| 5 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 2 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
|
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-5-Formyltetrahydrofolate
(6S)-5-Formyltetrahydrofolic acid
(6S)-Folinate
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
Fusilev
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
Levofolene
Levofolinate
Levofolinic acid
Levoleucovorin
Levo-leucovorin
L-Folinate
L-Folinic acid
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
| 6 |
|
Capecitabine |
Approved, Investigational |
Phase 2 |
|
154361-50-9 |
60953 |
|
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
| 7 |
|
Melphalan |
Approved |
Phase 2 |
|
148-82-3 |
4053 460612 |
|
Synonyms:
2-Amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoate
2-Amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoate
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
AIKERAN
ALANINE NITROGEN MUSTARD
Alkeran
CB-3025
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
L-PAM
L-Phenylalanine mustard
L-PHENYLALANINE MUSTARD (L-PAM)
L-SARCOLYSIN
L-Sarcolysine
L-Sarkolysin
Medphalan
MELFALAN
Melfalano
Melphalan
|
Melphalanum
Mephalan
Merphalan
MLP673
Mustard, phenylalanine
NCI-C04853
NSC-241286
NSC-8806
p-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
p-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
p-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
Sarcolysin
Sarcolysine
Sarkolysin
SK 15673
SK-15673
|
|
| 8 |
|
Floxuridine |
Approved |
Phase 2 |
|
50-91-9 |
5790 |
|
Synonyms:
1-(2-Deoxy-b-D-ribofuranosyl)-5-fluorouracil
1-(2-Deoxy-beta-D-ribofuranosyl)-5-fluorouracil
1-(2-Deoxy-β-D-ribofuranosyl)-5-fluorouracil
1b-D-2'-Deoxyribofuranosyl-5-flurouracil
1-b-D-2'-Deoxyribofuranosyl-5-flurouracil
1beta-D-2'-Deoxyribofuranosyl-5-flurouracil
1-beta-D-2'-Deoxyribofuranosyl-5-flurouracil
1Β-D-2'-deoxyribofuranosyl-5-flurouracil
1-Β-D-2'-deoxyribofuranosyl-5-flurouracil
2'-Deoxy-5-fluorouridine
5 Fluorodeoxyuridine
5FDU
5-Fluoro-2'-deoxyuridine
5-FLUORO-2-DEOXYURIDINE
5-Fluoro-2-desoxyuridine
5-Fluorodeoxyuridine
5-Fluorouracil 2'-deoxyriboside
5-Fluorouracil deoxyriboside
|
5-FUdR
b-5-Fluoro-2'-deoxyuridine
beta-5-Fluoro-2'-deoxyuridine
Deoxyfluorouridine
F.U.D.R.
FdU
FDUR
FDURD
FLOXIDINE
Floxiridina
Floxuridin
Floxuridine
Floxuridinum
Fluorodeoxyuridine
Fluoruridine deoxyribose
FUDR
NSC-27640
Β-5-fluoro-2'-deoxyuridine
|
|
| 9 |
|
Cetuximab |
Approved |
Phase 1, Phase 2 |
|
205923-56-4 |
|
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
| 10 |
|
Dexlansoprazole |
Approved, Investigational |
Phase 2 |
|
138530-94-6 |
9578005 |
|
Synonyms:
(+)-LANSOPRAZOL
(R)-LANSOPRAZOLE
2-((R)-((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole
DEXILANT
DEXILANT SOLUTAB
Dexlansoprazole
KAPIDEX
|
LANSOPRAZOLE R-FORM
R-lansoprazole
T 168390
T-168390
TAK 390
TAK-390
|
|
| 11 |
|
Clarithromycin |
Approved |
Phase 2 |
|
81103-11-9 |
84029 |
|
Synonyms:
6-O-METHYL ERYTHROMYCIN
6-O-Methylerythromycin
6-O-Methylerythromycin a
A-56268
ABBOTT-56268
Biaxin
BIAXIN XL
BIAXIN XL PAC
CAM
CLA
CLARIE XL
CLARITHROMYCIN
CLARITHROMYCIN EXTENDED RELEASE
CLARITHROMYCIN IDENTITY
Clarithromycina
Clarithromycine
|
Clarithromycinum
Claritromicina
CLAROSIP
Clathromycin
FEBZIN XL
KLARICID
KLARICID 500
KLARICID ADULT
KLARICID I.V.
KLARICID PAED
KLARICID XL
MYCIFOR XL
PREVPAC
TE-031
XETININ XL
ZECLAR
|
|
| 12 |
|
Carbamide peroxide |
Approved |
Phase 2 |
|
124-43-6 |
|
|
Synonyms:
Carbamide peroxide
Hydrogen peroxide carbamide
Urea dioxide
|
Urea hydrogen peroxide
Urea peroxide
|
|
| 13 |
|
Lansoprazole |
Approved, Investigational |
Phase 2 |
|
103577-45-3 |
3883 |
|
Synonyms:
2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)benzimidazole
A-65006
Abbot brand OF lansoprazole
AG 1749
AG-1749
Agopton
Almirall brand OF lansoprazole
Amarin
Aprazol
Bamalite
Biuret
Biuret Gr
Biuret Reagent
Biuret Reagent Solution
Blason
Compraz
Dakar
Hoechst brand OF lansoprazole
Hormona brand OF lansoprazole
Ilsatec
Ketian
Lancid
Lanfast
Lanproton
Lansol
Lansopep
Lansophed
Lansoprazol
Lansoprazol [INN-Spanish]
LANSOPRAZOLE
Lansoprazole [Usan:Ban:Inn]
Lansoprazole abbot brand
Lansoprazole almirall brand
Lansoprazole hoechst brand
Lansoprazole hormona brand
Lansoprazole lederle brand
Lansoprazole promeco brand
Lansoprazole salvar brand
Lansoprazole sodium
Lansoprazole takeda brand
Lansoprazole tap brand
Lansoprazole tecnobio brand
Lansoprazole vinas brand
Lansoprazole wyeth brand
Lansoprazoles
Lansoprazolum
|
Lansoprazolum [INN-Latin]
Lansox
Lanston
Lanz
Lanzo
Lanzol
Lanzol-30
Lanzopral
Lanzor
Lanzul
Lapraz
Lasoprol
Lederle brand OF lansoprazole
Limpidex
Linamarin
Mesactol
Monolitum
Ogast
Ogastro
Opiren
Prevacid
PREVACID (TN)
PREVACID 24HR
PREVACID DELAYED RELEASE
PREVACID IV
PREVACID SOLUTAB
Prevpac
Prezal
Pro ulco
Promeco
promeco Brand OF lansoprazole
Promp
Prosogan
Salvar brand OF lansoprazole
Sodium, lansoprazole
Suprecid
Takeda brand OF lansoprazole
Takepron
TAP brand OF lansoprazole
tecnobio Brand OF lansoprazole
Ulpax
Vinas brand OF lansoprazole
Wyeth brand OF lansoprazole
Zoprol
Zoton
|
|
| 14 |
|
Amoxicillin |
Approved, Vet_approved |
Phase 2 |
|
26787-78-0 |
33613 |
|
Synonyms:
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
6-(a-Amino-4-hydroxyphenylacetamido)penicillanic acid
6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin
6-(p-Hydroxy-a-aminophenylacetamido)penicillanate
6-(p-Hydroxy-a-aminophenylacetamido)penicillanic acid
6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanate
6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(p-Hydroxy-α-aminophenylacetamido)penicillanate
6-(p-Hydroxy-α-aminophenylacetamido)penicillanic acid
6-[[Amino(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9ci
a-Amino-p-hydroxybenzylpenicillin
Actimoxi
Almodan
alpha-Amino-p-hydroxybenzylpenicillin
AMC
Amix
AMIX 125
AMIX 250
AMIX 500
Amoclen
Amolin
Amopen
Amopenixin
Amoram
AMOX
Amox 250 cap 250MG
Amox 500 cap 500MG
Amox S 125 sus 125mg/5ML
Amox S 250 sus 250mg/5ML
Amoxi
Amoxibiotic
Amoxicaps
Amoxicilina
Amoxicilina [INN-Spanish]
Amoxicillin
Amoxicillin (anhydrous)
Amoxicillin and clavulanate potassium
Amoxicillin anhydrous
Amoxicillin clariana brand
AMOXICILLIN HYDRATE
Amoxicillin monopotassium salt
Amoxicillin monosodium salt
Amoxicillin pediatric
Amoxicillin sodium
Amoxicillin trihydrate
Amoxicillin(usan)
Amoxicillin, (r*)-isomer
Amoxicilline
Amoxicilline [INN-French]
Amoxicillinum
Amoxicillinum [INN-Latin]
Amoxid
Amoxiden
AMOXIDENT 250
AMOXIDENT 500
AMOXI-INJECT
Amoxil
AMOXIL FIZTAB
AMOXIL SF
Amoxi-mast
AMOXI-TABS
Amoxivet
Amoxycilin
Amoxycillin
AMOXYCILLIN ANHYDROUS
Amoxycillin trihydrate
Amoxycillin, ban
Amoxymed
AMPC
Amrit
Anemolin
Anhydrous, amoxicillin
Apo-amoxi
Apo-amoxi cap 250MG
Apo-amoxi cap 500MG
Apo-amoxi PWR for susp 125mg/5ML
Apo-amoxi PWR for susp 250mg/5ML
Apo-amoxi sugar free
AQUACIL
Aspenil
AUGMENTIN '125'
AUGMENTIN '200'
AUGMENTIN '250'
AUGMENTIN '400'
AUGMENTIN '500'
|
AUGMENTIN '875'
AUGMENTIN es-600
AX
Biomox
Bristamox
BRL 2333
BRL-2333
Cemoxin
Clamoxyl
Clamoxyl (SKB)
Clamoxyl g.a.
Clamoxyl parenteral
Clariana brand OF amoxicillin
D-(-)-alpha-Amino-p-hydroxybenzyl penicillin
D-(-)-alpha-Amino-p-hydroxybenzylpenicillin
D-(alpha-Amino-p-hydroxybenzyl)penicillin
D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid
D-Amoxicillin
DEDOXIL
Delacillin
Dispermox
Efpenix
Flemoxin
FLEMOXIN SOLUTAB
G.A., clamoxyl
Galenamox
Gen-amoxicillin 250MG
Gen-amoxicillin 500MG
Hiconcil
Histocillin
Hydroxyampicillin
Ibiamox
Imacillin
Lamoxy
Larotid
Metafarma capsules
Metifarma capsules
Moxacin
Moxal
Moxatag
Novamoxin cap 250MG
Novamoxin cap 500MG
Novamoxin sus 125mg/5ML
Novamoxin sus 250mg/5ML
NSC-277174
Nu-amoxi cap 250MG
Nu-amoxi cap 500MG
Nu-amoxi sus 125/5ML
Nu-amoxi sus 250mg/5ML
Ospamox
Pamoxicillin
Parenteral, clamoxyl
Penamox
Pfizer brand OF amoxicillin sodium salt
PHL-Amoxicillin
p-Hydroxyampicillin
Piramox
PMS-Amoxicillin
Polymox
Prevpac
Pro amox PWR for oral susp 125mg/5ML
Pro amox-250 cap 250MG
Pro amox-500 cap 500MG
Pro-amox-250 orl sus 250mg/5ML
RESPILLIN
R-Hydroxyampicillin
Rimoxallin
Robamox
Sauracillin
Sawamox PM
SmithKline beecham brand OF amoxicillin sodium salt
Sodium, amoxicillin
Sumox
Tolodina
Trihydrate, amoxicillin
Trimox
Unicillin
Utimox
Vetramox
VETREMOX
Wymox
Zimox
ZOXYCIL 250
ZOXYCIL 500
Α-amino-p-hydroxybenzylpenicillin
|
|
| 15 |
|
Oxaliplatin |
Approved, Investigational |
Phase 2 |
|
61825-94-3 |
43805 11947679 6857599 |
|
Synonyms:
ACT 078
ACT-078
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
Elplat
Foloxatine
JM-83
L-OHP
L-OHP CPD
MBP-426 (LIPOSOMAL OXALIPLATIN)
NSC-266046
Oxalatoplatin
|
Oxalatoplatinum
Oxaliplatin
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
RP-54780
SR-96669
Transplatin
|
|
| 16 |
|
Irinotecan |
Approved, Investigational |
Phase 2 |
|
97682-44-5, 100286-90-6 |
60838 |
|
Synonyms:
(+)-Irinotecan
7 Ethyl 10 hydroxycamptothecin
7-Ethyl-10-hydroxycamptothecin
Biotecan
Camptosar
Camptothecin 11
Camptothecin-11
CP0
CPT 11
CPT11
CPT-11
HSDB 7607
Irinophore C
IRINOTECAN
|
Irinotecan Hcl
Irinotecan hydrochloride
Irinotecan hydrochloride trihydrate
Irinotecan lactone
Irinotecan mylan
IRINOTECAN, CPT-11
Irinotecanum
Irinotecanum [INN-Latin]
Irrinotecan
NK012 Compound
sn 38
sn-38
sn38 CPD
|
|
| 17 |
|
Nintedanib |
Approved |
Phase 2 |
|
656247-17-5 |
135423438 9809715 |
|
Synonyms:
BIBF 1120
BIBF1120
BIBF-1120
BIBF-1120|BIBF1120|Ofev®|Vargatef®
INTEDANIB
|
METHYL (3Z)-3-[(4-{METHYL[(4-METHYLPIPERAZIN-1-YL)ACETYL]AMINO}ANILINO)(PHENYL)METHYLIDENE]-2-OXO-2,3-DIHYDRO-1H-INDOLE-6-CARBOXYLATE
NINTEDANIB
Nintedanib esylate
Ofev
Vargatef
|
|
| 18 |
|
Nivolumab |
Approved |
Phase 2 |
|
946414-94-4 |
|
|
Synonyms:
BMS-936558
BMS-936558|MDX-1106|ONO-4538|Opdivo®
MDX-1106
|
NIVOLUMAB
ONO-4538
OPDIVO
|
|
| 19 |
|
Ipilimumab |
Approved |
Phase 2 |
|
477202-00-9 |
|
|
Synonyms:
BMS-734016
Ipilimumab
MDX-010
MDX-010|MDX-101|MDX-CTLA-4|Yervoy®
|
MDX-101
MDX-CTLA-4
MOAB-CTLA-4
YERVOY
|
|
| 20 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 2 |
|
59-30-3 |
6037 |
|
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
| 21 |
|
Exatecan |
Investigational |
Phase 1, Phase 2 |
|
171335-80-1 |
18546929 151115 |
|
Synonyms:
|
| 22 |
|
Cola |
|
Phase 2 |
|
|
|
| 23 |
|
Angiogenesis Inhibitors |
|
Phase 2 |
|
|
|
| 24 |
|
Mitomycins |
|
Phase 2 |
|
|
|
| 25 |
|
Tubulin Modulators |
|
Phase 2 |
|
|
|
| 26 |
|
Antimitotic Agents |
|
Phase 2 |
|
|
|
| 27 |
|
Albumin-Bound Paclitaxel |
|
Phase 2 |
|
|
|
| 28 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
| 29 |
|
Antidotes |
|
Phase 2 |
|
|
|
| 30 |
|
Protective Agents |
|
Phase 2 |
|
|
|
| 31 |
|
Antimetabolites |
|
Phase 2 |
|
|
|
| 32 |
|
Immunosuppressive Agents |
|
Phase 2 |
|
|
|
| 33 |
|
Immunologic Factors |
|
Phase 2 |
|
|
|
| 34 |
|
Antineoplastic Agents, Alkylating |
|
Phase 2 |
|
|
|
| 35 |
|
Micronutrients |
|
Phase 2 |
|
|
|
| 36 |
|
Folate |
|
Phase 2 |
|
|
|
| 37 |
|
Vitamins |
|
Phase 2 |
|
|
|
| 38 |
|
Trace Elements |
|
Phase 2 |
|
|
|
| 39 |
|
Vitamin B9 |
|
Phase 2 |
|
|
|
| 40 |
|
Vitamin B Complex |
|
Phase 2 |
|
|
|
| 41 |
|
Anti-Infective Agents |
|
Phase 2 |
|
|
|
| 42 |
|
Gastrointestinal Agents |
|
Phase 2 |
|
|
|
| 43 |
|
Cytochrome P-450 Enzyme Inhibitors |
|
Phase 2 |
|
|
|
| 44 |
|
Cytochrome P-450 CYP3A Inhibitors |
|
Phase 2 |
|
|
|
| 45 |
|
Anti-Ulcer Agents |
|
Phase 2 |
|
|
|
| 46 |
|
Proton Pump Inhibitors |
|
Phase 2 |
|
|
|
| 47 |
|
Antibiotics, Antitubercular |
|
Phase 2 |
|
|
|
| 48 |
|
Anti-Bacterial Agents |
|
Phase 2 |
|
|
|
| 49 |
|
Antacids |
|
Phase 2 |
|
|
|
| 50 |
|
Antineoplastic Agents, Immunological |
|
Phase 2 |
|
|
|
Interventional clinical trials:
(show all 36)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Repetitive Electrostatic Pressurised Intraperitoneal Aerosol Chemotherapy With Oxaliplatin (ePIPAC-OX) as a Palliative Monotherapy for Isolated Unresectable Colorectal Peritoneal Metastases: Protocol of a Multicentre, Open-label, Single-arm, Phase II Study (CRC-PIPAC) |
Completed |
NCT03246321 |
Phase 2 |
|
| 2 |
Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C |
Completed |
NCT02040142 |
Phase 2 |
Mitomycin C |
| 3 |
A Phase 1/2 Dose Escalation Study With Expansion Cohorts to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies |
Completed |
NCT02963831 |
Phase 1, Phase 2 |
Durvalumab |
| 4 |
Phase II Trial of Adjuvant Thalidomide Following Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Carcinomatosis or Adenomucinosis From Colorectal/Appendiceal Cancer |
Completed |
NCT00310076 |
Phase 2 |
thalidomide |
| 5 |
Phase II Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Ovarian, or Other Gynecologic Primary Cancer |
Recruiting |
NCT05185947 |
Phase 2 |
Paclitaxel;Nilotinib |
| 6 |
Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes |
Recruiting |
NCT04907643 |
Phase 2 |
|
| 7 |
A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors |
Recruiting |
NCT04902872 |
Phase 1, Phase 2 |
CBX-12 |
| 8 |
Surufatinib and Sintilimab in Combination With Capecitabine in Patients With Previously Treated Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma : a Single-arm, a Single-center , Phase 2 Trial |
Recruiting |
NCT05472948 |
Phase 2 |
Surufatinib |
| 9 |
Phase II Single-Blind Randomized Trial Comparing Morbidity of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis |
Recruiting |
NCT03073694 |
Phase 2 |
Mitomycin c;Melphalan |
| 10 |
ICARuS (Intraperitoneal Chemotherapy After cytoReductive Surgery): A Multi-center, Randomized Phase II Trial of Early Post-operative Intraperitoneal Chemotherapy (EPIC) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) After Optimal Cytoreductive Surgery (CRS) for Neoplasms of the Appendix, Colon or Rectum With Isolated Peritoneal Metastasis |
Recruiting |
NCT01815359 |
Phase 2 |
HIPEC with Mitomycin-C;EPIC with FUDR and Leucovorin |
| 11 |
A Phase Ib/II Trial of JAB-21822 in Combination With Cetuximab in Patients With Advanced Colorectal Cancer, Small Intestine Cancer and Appendiceal Cancer With KRAS G12C Mutation |
Recruiting |
NCT05194995 |
Phase 1, Phase 2 |
JAB-21822;Cetuximab |
| 12 |
Clinical Trial to Define the Effect of Perioperative H. Pylori Eradication With Antibiotic Treatment on Long Term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Undergoing Cytoreductive Surgery/Hyperthermic Intraperitoneal Chemotherapy |
Active, not recruiting |
NCT02387203 |
Phase 2 |
PrevPac (Prevacid, Amoxicillin, Clarithromycin) |
| 13 |
Treatment of a Cancerous Disease of the Peritoneum With Complete Cytoreductive Surgery With Intraperitoneal Chemohyperthermia Using Oxaliplatin Plus Irinotecan |
Terminated |
NCT00180960 |
Phase 2 |
Oxaliplatin and irinotecan |
| 14 |
LCI-GI-APX-NIN-001: Nintedanib in Metastatic Appendiceal Carcinoma |
Terminated |
NCT03287947 |
Phase 2 |
nintedanib |
| 15 |
A Phase II Study of Nivolumab and Ipilimumab in Mucinous Colorectal and Appendiceal Tumors |
Terminated |
NCT03693846 |
Phase 2 |
Nivolumab;Ipilimumab |
| 16 |
Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous FOLFIRI (5-fluorouracil, Leucovorin and Irinotecan) for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer |
Completed |
NCT02833753 |
Phase 1 |
Oxaliplatin |
| 17 |
Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies |
Recruiting |
NCT04847063 |
Phase 1 |
Mitomycin C;Cisplatin;Doxorubicin;Oxaliplatin;5-Fluorouracil;Sodium Thiosulfate |
| 18 |
Safety and Efficacy of Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian, Uterine, Appendiceal, Colorectal, and Gastric Cancer Patients With Peritoneal Carcinomatosis (PC) |
Recruiting |
NCT04329494 |
Phase 1 |
Cisplatin;Doxorubicin;Fluorouracil;Irinotecan;Leucovorin;Mitomycin;Oxaliplatin |
| 19 |
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study |
Not yet recruiting |
NCT05277766 |
Phase 1 |
PIPAC with Nal-IRI |
| 20 |
Phase I Trial of Intraperitoneal Oxaliplatin in Combination With Intravenous mFOLFIRI for Peritoneal Carcinomatosis From Colorectal and Appendiceal Cancer |
Terminated |
NCT04158349 |
Phase 1 |
Oxaliplatin;mFOLFIRI |
| 21 |
Selective Rather Than Routine Histopathological Examination Following Appendectomy and Cholecystectomy; the FANCY Study. |
Unknown status |
NCT03510923 |
|
|
| 22 |
Multicenter, International Online Documentation of Indications and Results of Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC Und PITAC) for Treating Malignant Peritoneal and Pleural Diseases |
Unknown status |
NCT03210298 |
|
|
| 23 |
A Survey of the Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients |
Completed |
NCT02374411 |
|
|
| 24 |
Surgical Outcome and Predictors of Overall Survival of Stage I-III Appendiceal Adenocarcinoma; a National Cancer Database Analysis |
Completed |
NCT05452382 |
|
|
| 25 |
Distant Metastases and Long-Term Survival After Complete Resection of Neuroendocrine Tumors of the Appendix: An International Multicenter Study |
Completed |
NCT03852693 |
|
|
| 26 |
Trial of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Primary Peritoneal Cancers and Secondary Peritoneal Cancers From Stomach, Colorectal, Appendiceal, and/or Gynecological Origins |
Completed |
NCT03604653 |
|
Mitomycin c;CDDP 50;CDDP 75;Doxorubicin |
| 27 |
GI 1549: PROGRAMS TO SUPPORT YOU DURING CHEMOTHERAPY (PRO-YOU) A Randomized Controlled Pilot Study of Yoga Compared to an Attention Control in Patients Receiving Chemotherapy |
Completed |
NCT02489422 |
|
|
| 28 |
A Cohort Study of the Gastrointestinal Microbiome in Appendiceal Cancer With Peritoneal Spread |
Recruiting |
NCT02599116 |
|
|
| 29 |
A Phase II Trial to Analyze Clinical and Pharmacological Properties for Severe Neutropenia After Cytoreductive Surgery Followed by Hyperthermic Intraperitoneal Chemotherapy Using Mitomycin-C |
Recruiting |
NCT05513183 |
|
|
| 30 |
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT) |
Recruiting |
NCT04028479 |
|
Systemic Treatment (T) |
| 31 |
5-hydroxymethylation Signatures in Plasma Circulating Cell-free DNA as Markers for Tumor Burden and Recurrence in Appendiceal and Colorectal Peritoneal Metastasis |
Recruiting |
NCT04157322 |
|
|
| 32 |
The PANO Trial: Perioperative Exercise and Nutrition Optimisation Prehabilitation in Cancer Patients With Peritoneal Malignancy |
Recruiting |
NCT05305820 |
|
|
| 33 |
A Pragmatic, Single-Arm Clinical Trial of a Novel Dose Adjustment Algorithm for Preventing Cytopenia-Related Delays During FOLFOX Chemotherapy |
Recruiting |
NCT04526886 |
|
|
| 34 |
Characterisation of Appendiceal Cancer by Genomic and Transcriptomic Analysis and Correlation With Clinical Outcomes |
Not yet recruiting |
NCT05364788 |
|
|
| 35 |
The Prevalence of Appendiceal Tumours in Patients Presenting With a Periappendicular Abscess - A Nationwide Prospective Cohort Study |
Not yet recruiting |
NCT04634448 |
|
|
| 36 |
Justification of Incidental Appendectomy With Respect to Pathohistological Findings |
Not yet recruiting |
NCT05202600 |
|
|
|
